Skip to content

Author

R. Campbell

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Effects of empagliflozin according to background angiotensin receptor-neprilysin inhibitor and mineralocorticoid receptor antagonist use in heart failure with reduced ejection fraction (SUGAR-DM-HF)

The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces left ventricular (LV) volumes in heart failure with reduced ejection fraction (HFrEF). Whether this effect is additive to optimal background guideline-recommended therapy is unknown. To evaluate the effects of empagliflozin according to key...

M. Lee, C. Berry, R. Campbell et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.